What blood disorder is characterized by anemia, leukocytosis, and thrombocytosis?

Blood Disorder with Anemia, Leukocytosis, and Thrombocytosis

The most likely diagnosis is chronic myeloid leukemia (CML), though polycythemia vera (PV) and essential thrombocythemia (ET) should also be considered, with the key distinguishing feature being whether the anemia is true or relative.

Primary Differential Diagnosis

The combination of low hemoglobin, elevated white blood cell count, and elevated platelet count points to three main possibilities:

Chronic Myeloid Leukemia (CML)

CML classically presents with leukocytosis (often exceeding 100 × 10⁹/L), thrombocytosis, and anemia due to bone marrow infiltration 1. The disease shows:

• Increased bone marrow cellularity with proliferation of all stages of myelopoiesis
• Basophilia is common
• Anemia results from ineffective erythropoiesis and marrow replacement
• Diagnosis requires cytogenetics showing t(9;22)(q34;q11) and BCR-ABL1 transcripts by RT-PCR 1

About 50% of CML patients are asymptomatic at diagnosis, with the disease discovered incidentally on routine blood work 1. When symptomatic, patients present with fatigue, weight loss, splenomegaly (40-50% of cases), and left upper quadrant pain 1.

Polycythemia Vera (PV)

PV typically manifests with erythrocytosis (elevated hemoglobin), but patients often have leukocytosis and thrombocytosis as well 2, 3. The "anemia" in your question makes PV less likely unless:

• The patient has been phlebotomized
• There is concurrent iron deficiency from therapeutic phlebotomy
• The patient is in a spent phase transitioning to myelofibrosis

PV diagnosis requires JAK2 mutation testing (V617F or exon 12 mutations present in >95% of cases) 2, 3.

Secondary (Reactive) Thrombocytosis with Leukocytosis

Iron deficiency anemia can cause severe reactive thrombocytosis and leukocytosis 4. In one reported case, a patient with iron deficiency had hemoglobin of 5.4 g/dL, platelets of 2500 × 10⁹/L, and WBC of 35 × 10⁹/L, which resolved completely with iron supplementation 4. This is the most benign explanation but should only be diagnosed after excluding myeloproliferative neoplasms.

Diagnostic Algorithm

Step 1: Confirm the findings

• Repeat complete blood count with differential
• Peripheral blood smear to assess cell morphology, look for immature granulocytes, basophilia, and abnormal platelets

Step 2: Test for myeloproliferative neoplasms

• JAK2 V617F mutation testing (positive in >95% of PV, 50-60% of ET, and rare in CML) 2, 3
• BCR-ABL1 testing by RT-PCR to diagnose or exclude CML 1
• If JAK2 negative and BCR-ABL1 negative, test for calreticulin and MPL mutations 5

Step 3: Assess for secondary causes

• Iron studies with ferritin (iron deficiency can cause severe reactive thrombocytosis) 4, 5
• C-reactive protein (inflammation/infection can cause reactive changes) 5
• Evaluate for occult malignancy, chronic infection, or inflammatory conditions

Step 4: Bone marrow biopsy

• Required if myeloproliferative neoplasm is suspected and molecular testing is inconclusive 1, 5
• CML shows hypercellular marrow with myeloid predominance and small hypolobulated megakaryocytes 1

Critical Pitfalls to Avoid

• Do not assume reactive thrombocytosis without excluding myeloproliferative neoplasms, as these carry significant thrombotic risk and require specific management 6
• Do not overlook CML in younger patients—while often thought of as a disease of older adults, it can occur at any age
• Recognize that thrombosis may be the presenting feature of myeloproliferative neoplasms, especially in unusual sites (splanchnic, cerebral) 6
• Iron deficiency can mask PV—patients with PV who are iron deficient may have normal or low hemoglobin despite underlying erythrocytosis 3

Management Implications

The distinction matters critically for morbidity and mortality:

• CML requires tyrosine kinase inhibitor therapy (imatinib, dasatinib, nilotinib) targeting BCR-ABL1 1
• PV requires phlebotomy to maintain hematocrit <45%, low-dose aspirin, and cytoreductive therapy (hydroxyurea, ropeginterferon alfa-2b, or ruxolitinib) in high-risk patients 2, 3
• Reactive thrombocytosis resolves with treatment of the underlying cause (iron supplementation, treating infection/inflammation) 4

Without molecular testing (BCR-ABL1 and JAK2), you cannot definitively distinguish between these entities, and the treatment approaches differ fundamentally in terms of both mortality reduction and quality of life.